Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US FDA Would See Cash Windfall In COVID-19 Relief Bill

Executive Summary

The $500m in additional funds would support pandemic-related activities, potentially for additional staff or technology upgrades.

You may also be interested in...



Biden Leaves US FDA Largely Out Of Budget Outline

FDA is only mentioned once in the document, and its temporary leadership may not be the reason why.

Advanced Manufacturing May Require US FDA To Think Differently About Guidance

National Academies report argues that technologies cannot only be evaluated in the context of specific products, and FDA guidance should become both ‘more fluid and targeted.’

US COVID-19 Relief Package Boosts Pharma Manufacturing Programs – More To Come?

$10bn here and $6bn there on top of what’s left from earlier CARES Act gives government more options on COVID-19 medical countermeasures.

Related Content

Topics

UsernamePublicRestriction

Register

PS143766

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel